The Effect of Atorvastatin 80 mg on Hs-CRP/Albumin Ratio in Reducing Thrombus Burden in PCI-STEMI Patients

Universitas Sebelas Maret40 enrolled

Overview

40 STEMI patients who underwent primary PCI were subsequently allocated into two groups via a double-blind randomization method: An Atorvastatin 80 mg group and the control group. Levels of hs-CRP and albumin were assessed for both groups upon presentation at the emergency department before to initial PCI and were re-evaluated 24 hours after primary PCI. Thrombus burden was assessed using angiography with the TIMI Thrombus grade.

This study encompasses 40 STEMI patients who underwent primary PCI at Dr. Moewardi General Hospital in Central Java, Indonesia, between September and October. This study employed an experimental design with a pre-and-post technique, with participants recruited through sequential sampling. Patients were subsequently allocated into two groups via a double-blind randomization method. A treatment group was administered a loading dose of high-intensity statin (80 mg atorvastatin) upon initial presentation at the emergency department (ED), whereas the control group received no such intervention. Both cohorts received therapy in accordance with established guidelines prior to performing primary PCI. Levels of hs-CRP and albumin were assessed for both groups upon presentation at the emergency department before to initial PCI. In the treatment group, a second 80 mg dose of atorvastatin was provided 24 hours after the original dose. Both hs-CRP and albumin levels were re-evaluated 24 hours after primary PCI in both the control and treatment cohorts. Thrombus burden was assessed using angiography with the TIMI Thrombus grade

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

SINGLE

Enrollment

Conditions

STEMI (STE-ACS)Primary PCI for STEMI

Interventions

Atorvastatin 80mgDRUG

80 mg of Atorvastatin are loading in first medical contact (Emergency Department) before primary PCI

PlaceboDRUG

Only given a loading DAPT without loading Atorvastatin 80 mg

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * STEMI with onset less than 24 hour and undergo a Primary PCI Exclusion Criteria: * STEMI beyond 24 hours from the onset of chest pain * Prior statin therapy within the preceding 24 hours * Hypersensitivity to statins, pregnancy, lactation, severe inflammatory conditions including active liver dysfunction, chronic kidney disease (eGFR \<30 mL/min), autoimmune disorders, malignancy, severe malnutrition, and * Contraindications to statin administration.

Locations (1)

RSUD Dr Moewardi

Surakarta, Central Java, Indonesia

Outcomes

Primary Outcomes

hs-CRP/Albumin ratio

The administration of 80 mg atorvastatin significantly reducing the hs-CRP/Albumin ratio (Δ 0.35 ± 0.67; p \< 0.001) if compared to the control group

Time frame: From enrollment to the end of treatment at 3 days

Secondary Outcomes

TIMI Thrombus Burden

Using a TIMI Thrombus Burden that measure while performing PCI, we analyze that High burden thrombus was correlated with elevated of hs-CRP/Albumin ratio (r = 0.562; p = 0.012; r \> 0.05; p \< 0.05). So, by reducing Hs-CRP/Albumin Ratio, it appears also reducing the TIMI Thrombus burden.

Time frame: From enrollment to door to balloon time (Less than 24 hour onset)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.